vs

Side-by-side financial comparison of ServiceTitan, Inc. (TTAN) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

ServiceTitan, Inc. is the larger business by last-quarter revenue ($249.2M vs $139.1M, roughly 1.8× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 20.6% vs -15.9%, a 36.5% gap on every dollar of revenue. On growth, ServiceTitan, Inc. posted the faster year-over-year revenue change (25.0% vs 21.5%).

Alphabet Inc. is an American multinational technology conglomerate holding company headquartered in Mountain View, California. It was created through a restructuring of Google on October 2, 2015, and became the parent holding company of Google and several former Google subsidiaries. Alphabet is listed on the large-cap section of the Nasdaq under the ticker symbols GOOGL and GOOG; both classes of stock are components of major stock market indices such as the S&P 500 and Nasdaq-100. Alphabet ha...

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

TTAN vs VCYT — Head-to-Head

Bigger by revenue
TTAN
TTAN
1.8× larger
TTAN
$249.2M
$139.1M
VCYT
Growing faster (revenue YoY)
TTAN
TTAN
+3.5% gap
TTAN
25.0%
21.5%
VCYT
Higher net margin
VCYT
VCYT
36.5% more per $
VCYT
20.6%
-15.9%
TTAN

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
TTAN
TTAN
VCYT
VCYT
Revenue
$249.2M
$139.1M
Net Profit
$-39.5M
$28.7M
Gross Margin
70.8%
72.7%
Operating Margin
-16.9%
16.3%
Net Margin
-15.9%
20.6%
Revenue YoY
25.0%
21.5%
Net Profit YoY
14.9%
EPS (diluted)
$-0.42
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TTAN
TTAN
VCYT
VCYT
Q1 26
$139.1M
Q4 25
$249.2M
$140.6M
Q3 25
$242.1M
$131.9M
Q2 25
$215.7M
$130.2M
Q1 25
$209.3M
$114.5M
Q4 24
$199.3M
$118.6M
Q3 24
$115.9M
Q2 24
$170.3M
$114.4M
Net Profit
TTAN
TTAN
VCYT
VCYT
Q1 26
$28.7M
Q4 25
$-39.5M
$41.1M
Q3 25
$-32.2M
$19.1M
Q2 25
$-46.4M
$-980.0K
Q1 25
$-100.9M
$7.0M
Q4 24
$-46.5M
$5.1M
Q3 24
$15.2M
Q2 24
$-56.0M
$5.7M
Gross Margin
TTAN
TTAN
VCYT
VCYT
Q1 26
72.7%
Q4 25
70.8%
72.5%
Q3 25
70.8%
69.2%
Q2 25
68.8%
69.0%
Q1 25
66.0%
69.5%
Q4 24
65.2%
66.4%
Q3 24
68.2%
Q2 24
62.2%
68.1%
Operating Margin
TTAN
TTAN
VCYT
VCYT
Q1 26
16.3%
Q4 25
-16.9%
26.4%
Q3 25
-14.4%
17.4%
Q2 25
-23.0%
-4.0%
Q1 25
-47.7%
2.5%
Q4 24
-22.1%
3.5%
Q3 24
10.4%
Q2 24
-31.4%
4.0%
Net Margin
TTAN
TTAN
VCYT
VCYT
Q1 26
20.6%
Q4 25
-15.9%
29.3%
Q3 25
-13.3%
14.5%
Q2 25
-21.5%
-0.8%
Q1 25
-48.2%
6.2%
Q4 24
-23.3%
4.3%
Q3 24
13.1%
Q2 24
-32.9%
5.0%
EPS (diluted)
TTAN
TTAN
VCYT
VCYT
Q1 26
$0.35
Q4 25
$-0.42
$0.50
Q3 25
$-0.35
$0.24
Q2 25
$-0.51
$-0.01
Q1 25
$-3.34
$0.09
Q4 24
$-1.74
$0.07
Q3 24
$0.19
Q2 24
$-2.02
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TTAN
TTAN
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$493.2M
$439.1M
Total DebtLower is stronger
$103.6M
Stockholders' EquityBook value
$1.5B
$1.3B
Total Assets
$1.8B
$1.4B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TTAN
TTAN
VCYT
VCYT
Q1 26
$439.1M
Q4 25
$493.2M
$362.6M
Q3 25
$471.5M
$315.6M
Q2 25
$420.3M
$219.5M
Q1 25
$441.8M
$186.1M
Q4 24
$133.8M
$239.1M
Q3 24
$274.1M
Q2 24
$116.2M
$235.9M
Total Debt
TTAN
TTAN
VCYT
VCYT
Q1 26
Q4 25
$103.6M
Q3 25
$103.7M
Q2 25
$103.9M
Q1 25
$104.0M
Q4 24
$174.2M
Q3 24
Q2 24
Stockholders' Equity
TTAN
TTAN
VCYT
VCYT
Q1 26
$1.3B
Q4 25
$1.5B
$1.3B
Q3 25
$1.5B
$1.3B
Q2 25
$1.5B
$1.2B
Q1 25
$1.5B
$1.2B
Q4 24
$-576.8M
$1.2B
Q3 24
$1.2B
Q2 24
$-506.0M
$1.1B
Total Assets
TTAN
TTAN
VCYT
VCYT
Q1 26
$1.4B
Q4 25
$1.8B
$1.4B
Q3 25
$1.8B
$1.4B
Q2 25
$1.7B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.5B
$1.3B
Q3 24
$1.3B
Q2 24
$1.2B
Debt / Equity
TTAN
TTAN
VCYT
VCYT
Q1 26
Q4 25
0.07×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.07×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TTAN
TTAN
VCYT
VCYT
Operating Cash FlowLast quarter
$43.8M
$35.2M
Free Cash FlowOCF − Capex
$42.2M
FCF MarginFCF / Revenue
16.9%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.23×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TTAN
TTAN
VCYT
VCYT
Q1 26
$35.2M
Q4 25
$43.8M
$52.6M
Q3 25
$40.3M
$44.8M
Q2 25
$-14.6M
$33.6M
Q1 25
$5.4M
Q4 24
$15.5M
$24.5M
Q3 24
$30.0M
Q2 24
$-19.2M
$29.6M
Free Cash Flow
TTAN
TTAN
VCYT
VCYT
Q1 26
Q4 25
$42.2M
$48.8M
Q3 25
$39.2M
$42.0M
Q2 25
$-15.9M
$32.3M
Q1 25
$3.5M
Q4 24
$14.5M
$20.4M
Q3 24
$27.7M
Q2 24
$-19.9M
$26.8M
FCF Margin
TTAN
TTAN
VCYT
VCYT
Q1 26
Q4 25
16.9%
34.7%
Q3 25
16.2%
31.8%
Q2 25
-7.4%
24.8%
Q1 25
3.1%
Q4 24
7.3%
17.2%
Q3 24
23.9%
Q2 24
-11.7%
23.4%
Capex Intensity
TTAN
TTAN
VCYT
VCYT
Q1 26
Q4 25
0.6%
2.7%
Q3 25
0.5%
2.1%
Q2 25
0.6%
1.0%
Q1 25
1.6%
Q4 24
0.5%
3.5%
Q3 24
1.9%
Q2 24
0.4%
2.4%
Cash Conversion
TTAN
TTAN
VCYT
VCYT
Q1 26
1.23×
Q4 25
1.28×
Q3 25
2.34×
Q2 25
Q1 25
0.76×
Q4 24
4.80×
Q3 24
1.98×
Q2 24
5.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TTAN
TTAN

Subscription Revenue$182.8M73%
Usage Revenue$56.8M23%
Professional Services And Other Revenue$9.6M4%

VCYT
VCYT

Testing revenue$135.1M97%
Product revenue$3.7M3%
Biopharmaceutical and other revenue$301.0K0%

Related Comparisons